Low incidence, good outcomes in myopericarditis after COVID-19 mRNA vaccination

Amongst adolescents and young adults who received the COVID-19 mRNA vaccine, the associated myopericarditis incidence rate was low, with mostly favorable early outcomes, according to a systematic review and meta-analysis published in JAMA Pediatrics.

Researchers identified 23 observational studies including 854 individuals between the ages of 12 to 20 years with COVID-19 vaccine–associated myopericarditis; the majority of which were male (90.3%).

Nearly 75% of events occurred after the second dose. Left ventricular (LV) function was preserved in 84.4% of patients, and of the 15.6% with LV systolic dysfunction, 14.1% and 1.3% were mild and severe, respectively.

Late gadolinium enhancement was found on cardiac magnetic resonance imaging in 87.2% of patients.

Most patients required hospitalization (92.6%), however, only 23.2% were admitted to the ICU and only 1.3% required inotropes. No patient died or required mechanical support.

Reference
Yasuhara J, Masuda K, Aikawa T, et al. Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults: A Systematic Review and Meta-analysis. JAMA Pediatr.  2022. doi:10.1001/jamapediatrics.2022.4768